After a one-year gap, Sage finally finds new CMO; Gutted by layoffs, Flagship's Rubius reshuffles a not-so-full deck
Late last year, Sage’s chief medical officer Stephen Kanes left to head a new depression drug developer in Ancora. Now, one year later, Sage has finally found his replacement in Laura Gault.
Gault comes to Sage from Alexion, AstraZeneca’s rare disease arm, where she was head of neurology and ophthalmology and led the Ultomiris program for myasthenia gravis and NMOSD. In April, Ultomiris was approved for adults with myasthenia gravis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.